Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Core Insights - Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious hematologic diseases [3] - The company will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025 [1] - A live webcast of the event will be available on the company's investor relations website, with an archived replay accessible afterward [2] Company Overview - Disc Medicine is committed to discovering and commercializing innovative treatments targeting red blood cell biology, specifically heme biosynthesis and iron homeostasis [3] - The company aims to build a portfolio of potentially first-in-class therapeutic candidates addressing a wide spectrum of hematologic diseases [3]